Rich Silva

Rich Silva joins Carmot Therapeutics as the new Vice President of Chemistry, Manufacturing, and Controls (CMC). Rich’s 25-year career includes extensive experience in the commercialization of innovative therapies, as well as collaborations with leading global pharmaceutical companies.

Prior to joining Carmot Therapeutics, Rich held the position of Head of Technical Operations at Epizyme, where he managed pharmaceutical development, including drug substance synthesis, drug product formulation, and analytical method development. During his tenure, Rich led the post-launch development and manufacturing of Epizyme’s epigenetic therapy, Tazverik (tazemetostat), ensuring a robust commercial supply chain, compliance with Good Manufacturing Practices (GMP), and regulatory commitments, as well as technical oversight of drug substance (API) and drug product (DP) manufacturing processes. Additionally, Rich’s group advanced several candidates for first-in-human trials by providing a phase-appropriate supply of drug substance and product, utilizing Quality by Design (QbD) principles.

Before his time at Epizyme, Rich served as Senior Director of Small Molecules Process Chemistry and Analytical at ImmunoGen, where he played a crucial role in the development and commercialization of ImmunoGen’s antibody-drug conjugate (ADC), ELAHERE (mirvetuximab soravtansine). In this capacity, he oversaw the optimization of synthetic routes, scale-up of process chemistry, and implementation of analytical methods to ensure product quality.

Rich’s career also includes positions of increasing responsibility at Genzyme, Vertex, and Bayer Chemicals, where he applied his expertise in organic chemistry, process development, and analytical techniques to advance various drug candidates. Rich earned his Ph.D. in Organic Chemistry from Dartmouth College.